{
    "info": {
        "nct_id": "NCT03949270",
        "official_title": "BETA-Text: Evaluating the Efficacy of a Novel, Interactive, Bidirectional Text-messaging Application to Increase Persistence to Adjuvant Endocrine Therapy for Stage I-III Hormone Receptor Positive Breast Cancer",
        "inclusion_criteria": "1. Patients with histologically confirmed stage I-III, estrogen and/or progesterone receptor positive, as defined by ASCO-CAP guidelines, invasive breast cancer for whom adjuvant hormonal therapy is indicated following standard NCCN practice guidelines.42\n2. Patients must initiate an aromatase inhibitor (AI), with the choice of AI (letrozole, anastrozole, or exemestane) left to the discretion of the treating provider (have just started or plan to start within 4 weeks)\n3. Patients with synchronous bilateral breast cancers are eligible if both tumors are hormone receptor positive.\n4. Patient must be able to provide informed consent and agree to:\n\n   1. Complete questionnaires according to the pre-specified study design\n   2. Own or have access to a personal cell phone, agree to send and receive text messages (including any costs), and share their personal cell phone number to receive text messages.\n   3. Be able to read/speak English\n   4. To allow research staff to contact their pharmacies to determine prescription refill dates.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Patients with history of prior stage I-III breast cancer in the same or contralateral breast are not eligible (because exposure to prior endocrine therapy may confound results)\n2. Patients with metastatic breast cancer.\n3. Patients with ductal carcinoma in situ (DCIS) or other pre-malignant lesions of the breast receiving endocrine therapy as chemoprevention.\n4. Prior treatment with an aromatase inhibitor, regardless of indication.\n5. Prior tamoxifen for the current cancer (prior tamoxifen for DCIS or a different cancer is permitted).",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must be FEMALE",
            "criterions": [
                {
                    "exact_snippets": "Must be FEMALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Complete questionnaires according to the pre-specified study design",
            "criterions": [
                {
                    "exact_snippets": "Complete questionnaires according to the pre-specified study design",
                    "criterion": "questionnaire completion",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "adherence to study design",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. To allow research staff to contact their pharmacies to determine prescription refill dates.",
            "criterions": [
                {
                    "exact_snippets": "allow research staff to contact their pharmacies to determine prescription refill dates",
                    "criterion": "permission for research staff to contact pharmacies",
                    "requirements": [
                        {
                            "requirement_type": "permission",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Own or have access to a personal cell phone, agree to send and receive text messages (including any costs), and share their personal cell phone number to receive text messages.",
            "criterions": [
                {
                    "exact_snippets": "Own or have access to a personal cell phone",
                    "criterion": "personal cell phone",
                    "requirements": [
                        {
                            "requirement_type": "ownership or access",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agree to send and receive text messages (including any costs)",
                    "criterion": "text messaging",
                    "requirements": [
                        {
                            "requirement_type": "willingness to send and receive",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "share their personal cell phone number to receive text messages",
                    "criterion": "personal cell phone number",
                    "requirements": [
                        {
                            "requirement_type": "willingness to share",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Patients with synchronous bilateral breast cancers are eligible if both tumors are hormone receptor positive.",
            "criterions": [
                {
                    "exact_snippets": "Patients with synchronous bilateral breast cancers",
                    "criterion": "synchronous bilateral breast cancers",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "both tumors are hormone receptor positive",
                    "criterion": "hormone receptor status of both tumors",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Patient must be able to provide informed consent and agree to:",
            "criterions": [
                {
                    "exact_snippets": "Patient must be able to provide informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "ability to provide",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Patients must initiate an aromatase inhibitor (AI), with the choice of AI (letrozole, anastrozole, or exemestane) left to the discretion of the treating provider (have just started or plan to start within 4 weeks)",
            "criterions": [
                {
                    "exact_snippets": "Patients must initiate an aromatase inhibitor (AI) ... (have just started or plan to start within 4 weeks)",
                    "criterion": "aromatase inhibitor (AI) initiation",
                    "requirements": [
                        {
                            "requirement_type": "initiation status",
                            "expected_value": [
                                "just started",
                                "plan to start within 4 weeks"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Be able to read/speak English",
            "criterions": [
                {
                    "exact_snippets": "Be able to read/speak English",
                    "criterion": "English language ability",
                    "requirements": [
                        {
                            "requirement_type": "reading ability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "speaking ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Patients with histologically confirmed stage I-III, estrogen and/or progesterone receptor positive, as defined by ASCO-CAP guidelines, invasive breast cancer for whom adjuvant hormonal therapy is indicated following standard NCCN practice guidelines.42",
            "criterions": [
                {
                    "exact_snippets": "histologically confirmed stage I-III ... invasive breast cancer",
                    "criterion": "breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "estrogen and/or progesterone receptor positive, as defined by ASCO-CAP guidelines",
                    "criterion": "hormone receptor status",
                    "requirements": [
                        {
                            "requirement_type": "estrogen receptor status",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "progesterone receptor status",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "definition guideline",
                            "expected_value": "ASCO-CAP"
                        }
                    ]
                },
                {
                    "exact_snippets": "for whom adjuvant hormonal therapy is indicated following standard NCCN practice guidelines",
                    "criterion": "adjuvant hormonal therapy indication",
                    "requirements": [
                        {
                            "requirement_type": "indication",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "guideline",
                            "expected_value": "NCCN"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "4. Prior treatment with an aromatase inhibitor, regardless of indication.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with an aromatase inhibitor",
                    "criterion": "aromatase inhibitor treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of prior treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Patients with history of prior stage I-III breast cancer in the same or contralateral breast are not eligible (because exposure to prior endocrine therapy may confound results)",
            "criterions": [
                {
                    "exact_snippets": "history of prior stage I-III breast cancer in the same or contralateral breast are not eligible",
                    "criterion": "history of prior stage I-III breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "same breast",
                                "contralateral breast"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Patients with ductal carcinoma in situ (DCIS) or other pre-malignant lesions of the breast receiving endocrine therapy as chemoprevention.",
            "criterions": [
                {
                    "exact_snippets": "ductal carcinoma in situ (DCIS) or other pre-malignant lesions of the breast",
                    "criterion": "breast pre-malignant lesions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "receiving endocrine therapy as chemoprevention",
                    "criterion": "endocrine therapy as chemoprevention",
                    "requirements": [
                        {
                            "requirement_type": "receiving",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Patients with metastatic breast cancer.",
            "criterions": [
                {
                    "exact_snippets": "Patients with metastatic breast cancer",
                    "criterion": "breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": "metastatic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Prior tamoxifen for the current cancer (prior tamoxifen for DCIS or a different cancer is permitted).",
            "criterions": [
                {
                    "exact_snippets": "Prior tamoxifen for the current cancer",
                    "criterion": "prior tamoxifen use for the current cancer",
                    "requirements": [
                        {
                            "requirement_type": "history of use",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}